Topline klinische onderzoeksresultaten toonden aan dat LEUKINE® veilige, goed verdragen en gegenereerde T-cellen was gericht tegen het SARS-CoV-2-virus bij patiënten die in het ziekenhuis waren opgenomen met COVID-19

LEUKINE® wordt momenteel beoordeeld in een klinische studie in de VS bij COVID-19-patiënten

CHARLOTTE, N.C. – (BUSINESS WIRE) – Tanner Pharma Group (Tanner) heeft vandaag de uitbreiding aangekondigd van het LEUKINE Access Program (LeAP) als kanaal voor de distributie van LEUKINE® (sargramostim) op internationale markten. LEUKINE®, goedgekeurd door de Amerikaanse FDA in 1991 en nu vervaardigd door Partner Therapeutics (PTx), is een recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) die het immuunsysteem stimuleert en is gebruikt bij leukemiepatiënten om het risico te verminderen van infectie.

Tanner Pharma Group Expands Ex-US Access Program to Provide LEUKINE® for Use in Patients with Respiratory Illness Associated with COVID-19

Topline clinical trial results showed LEUKINE® was safe, well tolerated and generated T cells targeted at the SARS-CoV-2 virus in patients hospitalized with COVID-19

LEUKINE® is currently being assessed in a clinical trial in US in COVID-19 patients

CHARLOTTE, N.C.–(BUSINESS WIRE)– Tanner Pharma Group (Tanner) today announced expansion of the LEUKINE Access Program (LeAP) as a channel for distribution of LEUKINE® (sargramostim) in international markets. LEUKINE®, approved by the US FDA in 1991 and now manufactured by Partner Therapeutics (PTx), is a recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) that stimulates the immune system and has been used in leukemia patients to reduce the risk of infection.

PTx recently announced that a clinical trial of Leukine® conducted in Belgium of hospitalized COVID-19 patients suffering from acute hypoxic respiratory failure requiring supplemental oxygen met the primary endpoint of significant improvement in lung function. Improvement in oxygenation of at least 33% or more from baseline was seen in 54% of patients on the LEUKINE® plus standard-of-care (SOC) arm versus 26% of patients on SOC (p=.0147).

Tanner provides a regulatory-compliant pathway to make LEUKINE® available in international markets. If a patient is in a country where LEUKINE® is not available commercially physicians may be able to have Leukine® imported for their patients through named patient supply via LeAP managed by Tanner.

“As demonstrated by these positive clinical trial results, LEUKINE® has the potential to help COVID-19 patients,” said Banks Bourne, CEO of Tanner Pharma Group. “Our team is incredibly honored to be trusted with this important role, and we are mobilized to help patients and clinicians around the world gain access.”

LEUKINE® is currently being assessed in a clinical trial in the United States (NCT04411680) to further measure impact on COVID-19 patients.

For more information about this program or to request access to LEUKINE®, please call +1 704 643 8989 or email leukine@tannerpharma.com

About Tanner Pharma Group

Tanner Pharma Group partners with biopharmaceutical companies to provide turn-key solutions that increase patient access to medicines around the world. With an unparalleled blend of local market knowledge and international supply chain expertise across more than 130 countries, Tanner provides tailored solutions to biopharmaceutical companies outside their core markets of focus. For more information, visit www.tannerpharma.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210308005639/en/

Contacts

Christine Quern

CBQ Communications

cq@christinequern.com
617.650.8497